Skip to main
DWTX
DWTX logo

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. has raised its 12-month price target from $10.00 to $12.00, reflecting optimism regarding the future revenue potential associated with new product assets and strategic partnerships. The company's recent licensing agreement with Serpin Pharma for the global rights to SP16 reinforces its commitment to developing therapies that address significant unmet medical needs, particularly in cancer-related pain. Additionally, Dogwood's focus on innovative antiviral therapies positions it favorably within the biotechnology sector, enhancing prospects for future growth.

Bears say

Dogwood Therapeutics Inc, previously known as Virios Therapeutics Inc, faces challenges in advancing its antiviral therapies, particularly in addressing diseases linked to viral-triggered immune responses. The company's product candidates, IMC-1 and IMC-2, are in the development stage, which inherently involves significant risks and uncertainties regarding their commercial viability and potential regulatory hurdles. Additionally, the lack of established market presence and competition within the biotechnology sector raises concerns about the firm's ability to secure necessary funding and achieve sustainable growth.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.